- The Company Maintains Fiscal 2026 Guidance -
PIOMBINO DESE, Italy--(BUSINESS WIRE)--May 07, 2026--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026.
First Quarter of 2026 Highlights (comparisons to prior-year period)
-- For the first quarter of 2026, revenue increased 7% (10% on a constant
currency basis) to EUR273.6 million, with high-value solutions
representing 47% of total revenue.
-- Gross profit margin increased 30 basis points to 27.5%.
-- Adjusted EBITDA margin increased 150 basis points to 23.9%.
-- Diluted earnings per share were EUR0.10, and adjusted diluted earnings
per share were EUR0.11.
-- The Company is maintaining its fiscal 2026 guidance and still expects
revenue in the range of EUR1.26 billion to EUR1.29 billion, adjusted
EBITDA in the range of EUR331.8 million to EUR346.9 million, and adjusted
diluted EPS in the range of EUR0.59 to EUR0.63.
First Quarter 2026 Results
For the first quarter of 2026, total revenue increased 7% year-over-year (10% on a constant currency basis) to EUR273.6 million, driven by a 13% revenue increase (16% on a constant currency basis) from the Company's Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the revenue decline from the Engineering Segment. Revenue from high-value solutions increased 17%, year-over-year, to EUR128.6 million, and represented 47% of total revenue for the first quarter of 2026.
In the first quarter of 2026, gross profit margin increased 30 basis points to 27.5% driven by: (i) the ongoing improvements in Fishers and Latina as the new facilities continue to scale, (ii) an increase in high-value solutions, and (iii) improved marginality in the Engineering Segment. These positive trends were partially offset by the expected higher depreciation and the effects of foreign currency translation in the first quarter of 2026. Operating profit margin improved 70 basis points to 14.2%.
Net profit was EUR28.0 million for the first quarter of 2026, with diluted earnings per share of EUR0.10. For the first quarter of 2026, adjusted net profit increased to EUR29.6 million and adjusted diluted earnings per share increased to EUR0.11, compared with EUR0.10 for the same period last year.
For the first quarter of 2026, adjusted EBITDA increased to EUR65.5 million, and adjusted EBITDA margin improved 150 basis points to 23.9%, compared with the same period last year.
Franco Stevanato, Chief Executive Officer, commented, "The first quarter was a solid start to 2026, highlighted by strong momentum in the BDS Segment which delivered 16% growth at constant currency rates, driven by revenue increases across most product categories in both high-value and standard products. As expected, higher depreciation tempered gross profit margins in the quarter but results also reflect financial improvements in Fishers and Latina as we scale production, which in turn is driving the increase in high-value solutions. Revenue from biologics, which is our fastest growing end market, increased 15%, compared to the prior-year period, driven by GLP1s which accounted for approximately 21% to 22% of total Company revenue. Our success in this blockbuster treatment class demonstrates the trust and reliability that customers place on Stevanato Group to deliver high quality products at scale for their most valuable drug assets."
Biopharmaceutical and Diagnostic Solutions (BDS) Segment
Revenue grew 13% (16% on a constant currency basis) to EUR249.0 million for the first quarter of 2026, compared with the same period last year, driven by growth in high value and standard products.
In the first quarter of 2026, revenue from high-value solutions increased 17% to EUR128.6 million, and represented 52% of BDS Segment revenue, driven predominantly by high-performance syringes and, to a lesser extent, EZ-fill$(R)$ vials. Revenue from other containment and delivery solutions increased 9% to EUR120.3 million, compared with the same period last year, driven mostly by standard syringes and cartridges, which offset a lower revenue from IVD services.
For the first quarter of 2026, gross profit increased EUR1.2 million driven by the ramp up in Fishers and Latina and the favorable mix shift in high-value solutions. This was partially offset by: (i) higher depreciation, which was the largest headwind to gross profit, as more manufacturing lines are put into commercial service, (ii) the unfavorable effects of foreign currency, (iii) lower revenue and profit from an accretive pilot project with an industry-leading customer for large-batch, Not for Human Use (NFHU) fill and finish services, which did not recur in the first quarter of 2026, and (iv) the unfavorable impact from tariffs. As a result, gross profit margin decreased 300 basis points to 28.3%.
Engineering Segment
Revenue from the Engineering Segment decreased 31% to EUR24.6 million for the first quarter of 2026, compared with the same period last year, driven by lower revenue from glass converting and assembly manufacturing, which offset growth in pharmaceutical visual inspection.
For the first quarter of 2026, gross profit margin for the Engineering Segment increased 460 basis points to 15.3%, compared with the same period last year, as the Company begins to realize the benefits from the actions taken under its business optimization plan. This includes right-sizing operations and an improved labor cost structure which led to better financial performance in the Company's Denmark operations. While actions under the optimization plan are starting to gain traction, the Company remains cautious given the current slow pace of orders.
Balance Sheet and Cash Flow
As of March 31, 2026, the Company had cash and cash equivalents of EUR111.7 million, and net debt of EUR337.7 million.
For the first quarter of 2026, capital expenditures totaled EUR67.6 million, as the Company continues to increase capacity in its new manufacturing facilities in Indiana and Italy. For the three-months ended March 31, 2026, cash flow from operating activities was EUR75.5 million and cash used for the purchase of property, plant, and equipment, and intangible assets totaled EUR70.7 million. As a result, the Company generated EUR5.5 million of positive free cash flow for the first quarter of 2026.
The Company believes that it has adequate liquidity to fund its strategic priorities over at least the next twelve months through a combination of cash on hand, cash generated from operations, available credit lines, and the ability to access additional financing.
2026 Guidance
The Company is maintaining its fiscal 2026 guidance and continues to expect:
-- Revenue in the range of EUR1.26 billion to EUR1.29 billion;
-- Adjusted EBITDA in the range of EUR331.8 million to EUR346.9 million;
and
-- Adjusted diluted EPS in the range of EUR0.59 to EUR0.63.
Franco Stevanato concluded, "Looking ahead, our strategic investments and focus on high-value, scalable solutions position us to capitalize on the accelerating growth in biologics and injectable therapies. With our operational flexibility and competitive leadership in core product categories, we are confident in our ability to support customers and drive future success."
Conference call: The Company will host a conference call and webcast at 8:30 a.m. $(ET)$ on Thursday, May 7, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Investor Relations section of the Company's website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: Pre-registration for STVN Q1 2026 earnings webcast.
Webcast: A live, listen-only webcast of the call will be available at the following link: STVN Q1 2026 webcast.
Dial in: Those who are unable to pre-register may dial in by calling:
Italy: +39 02 802 09 11 United Kingdom: +44 1 212 818004 United States: +1 718 705 8796 United States Toll Free: +1 855 265 6958
Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: STVN Q1 2026 Link for Questions
Replay: The webcast will be archived for three months on the Company's Investor Relations section of its website.
Forward-Looking Statements
This press release may include forward-looking statements. The words "expects," "scale," "driving," "increase," "begins," "are starting," "remains," "continues," "believes," "expect," "position," "accelerating, " "drive," and other similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial performance, including revenue, operating expenses and ability to maintain profitability, and operational and commercial capabilities; the Company's expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company's plants and sites, and our expectations related to our capacity expansion; the global supply chain and the Company's committed orders; customer demand; the success of the Company's initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company's geographical and industrial footprint; and the Company's goals, strategies,
and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future, and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global and domestic economic and political conditions, inflation, trade war and global tariff policies, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, the Iran regional conflict (including U.S. participation), supply chain and logistical challenges and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company's future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F, and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements.
Non-GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures.
Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Consolidated Income Statement
(Amounts in EUR millions, except per share data)
For the three months
ended March 31,
2026 % 2025 %
Revenue 273.6 100.0% 256.6 100.0%
Costs of sales 198.4 72.5% 186.7 72.8%
----- ----- ----- -----
Gross Profit 75.2 27.5% 69.9 27.2%
Other operating
Income 1.4 0.5% 1.1 0.4%
Selling and
Marketing
Expenses 6.7 2.5% 6.0 2.3%
Research and
Development
Expenses 5.8 2.1% 5.9 2.3%
General and
Administrative
Expenses 25.3 9.2% 24.5 9.6%
----- ----- ----- -----
Operating Profit 38.7 14.2% 34.6 13.5%
Finance Income 3.4 1.2% 6.0 2.2%
Finance Expense 2.9 1.0% 5.5 2.1%
----- ----- ----- -----
Profit Before Tax 39.2 14.3% 35.1 13.7%
Income Taxes 11.2 4.1% 8.6 3.3%
----- ----- ----- -----
Net Profit 28.0 10.2% 26.5 10.3%
Earnings per
share
Basic earnings per
ordinary share 0.10 0.10
Diluted earnings
per ordinary
share 0.10 0.10
Average shares
outstanding 273.0 272.9
Average shares
assuming dilution 273.0 272.9
Reported Segment Information
(Amounts in EUR millions)
For the three months ended March 31, 2026
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 249.0 24.6 -- 273.6
Inter-Segment 0.3 31.0 (31.2) --
----------------- ----------- ------------ ------------
Revenue 249.2 55.6 (31.2) 273.6
----------------- ----------- ------------ ------------
Gross Profit 70.5 8.5 (3.9) 75.2
----------------- ----------- ------------ ------------
Gross Profit
Margin 28.3% 15.3% 27.5%
----------------- ----------- ------------ ------------
Operating Profit 44.1 3.7 (9.1) 38.7
----------------- ----------- ------------ ------------
Operating Profit
Margin 17.7% 6.6% 14.2%
----------------- ----------- ------------ ------------
For the three months ended March 31, 2025
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 220.8 35.7 -- 256.6
Inter-Segment 0.4 42.4 (42.8) --
----------------- ----------- ------------ ------------
Revenue 221.2 78.2 (42.8) 256.6
----------------- ----------- ------------ ------------
Gross Profit 69.3 8.3 (7.7) 69.9
----------------- ----------- ------------ ------------
Gross Profit
Margin 31.3% 10.7% 27.2%
----------------- ----------- ------------ ------------
Operating Profit 41.5 3.7 (10.6) 34.6
----------------- ----------- ------------ ------------
Operating Profit
Margin 18.8% 4.7% 13.5%
----------------- ----------- ------------ ------------
Cash Flow
(Amounts in EUR millions)
For the three months
ended March 31,
2026 2025
----------- ---------
Cash flow from operating activities 75.5 99.8
Cash flow used in investing activities (70.4) (70.7)
Cash flow used in financing activities (24.9) (35.7)
---------- ---------
Net change in cash and cash
equivalents (19.8) (6.6)
---------- ---------
Non-GAAP Financial Information
(MORE TO FOLLOW) Dow Jones Newswires
May 07, 2026 06:30 ET (10:30 GMT)